Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(CSE:BNXT)

0.3400 -0.0050 (-1.45%)
Streaming Delayed Price Updated: 12:17 PM EDT, Aug 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BNXT

< Previous 1 2 3 Next >
News headline image
BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Provides Development, Intellectual Property and Commercial Update Across Sublingual Drug Delivery Pipeline
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Advances GLP-1 Sublingual Semaglutide ODF Program with Next Stage of Delivery Development Underway
From BioNxt Solutions Inc.
Via ACCESS Newswire
News headline image
BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development
Via ACCESS Newswire
News headline image
BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum
Via ACCESS Newswire
News headline image
BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS)
Via ACCESS Newswire
News headline image
BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries
Via ACCESS Newswire
News headline image
BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy
Via ACCESS Newswire
News headline image
BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform
Via ACCESS Newswire
News headline image
BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe
Via ACCESS Newswire
News headline image
BioNxt Receives Milestone EPO Decision to Grant European Patent for Sublingual Cladribine Drug Delivery Technology for Multiple Sclerosis
Via ACCESS Newswire
News headline image
BioNxt Secures Innovative Chaperone Technology to Enhance Oral Thin-Film Drug Delivery
Via ACCESS Newswire
News headline image
BioNxt Reports Final Preclinical Results Demonstrating Approximately 40% Higher Cladribine Delivery for the Treatment Multiple Sclerosis (MS)
Via ACCESS Newswire
News headline image
BioNxt Reports Successful Final In-Vivo Dosing Study Results Supporting Superior Bioavailability of Cladribine Sublingual ODF
Via ACCESS Newswire
News headline image
Over 40% of Adults Struggle to Swallow Pills - BioNxt Targets a Global Adherence Problem with Rapid-Dissolving Thin-Film “Melt-in-Your-Mouth” Therapies
Via ACCESS Newswire
News headline image
BioNxt Advances "Melt in Your Mouth" Cladribine Formulation to Improve Treatment for MS Patients with Dysphagia
Via ACCESS Newswire
News headline image
BioNxt Signs Letter Agreement to Acquire 100% Interest in IP and to Codevelop a Sublingual Drug Formulation for Chemotherapy and Immunosuppressant Treatments
Via ACCESS Newswire
News headline image
BioNxt Secures Final Patent Grant from the Eurasian Patent Organization for Sublingual Cladribine Platform
Via ACCESS Newswire
News headline image
BioNxt Reports “Intention to Grant” Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
VANCOUVER, BC / November 4, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Intention to Grant" Patent Notification from the European Patent Office for Its Oral Cladribine Sublingual Thin-Film as the Multiple Sclerosis Market Shifts Toward Patient-Friendly Therapies
Via ACCESS Newswire
News headline image
BioNxt Reports “Readiness to Grant” Patent Notification from the Eurasian Patent Organization
VANCOUVER, BC / October 30, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Reports "Readiness to Grant" Patent Notification from the Eurasian Patent Organization
Via ACCESS Newswire
News headline image
BioNxt Enters the Final Stretch Before Human Trials for Next-Generation MS Drug
BioNxt Solutions Inc. (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience company developing next-generation drug delivery technologies, has launched a 15-day dosing optimization study for its lead... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
VANCOUVER, BC / October 21, 2025 / BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies,... 
Via PressReach
Topics Intellectual Property
News headline image
BioNxt Launches 15-day Sublingual Cladribine Dosing Optimization Study in Preparation for Human Bioequivalence Study
Via ACCESS Newswire
News headline image
BioNxt Completes "Fast-Track" US Track One Patent Filing for Sublingual Delivery of Cladribine for the Treatment of Multiple Sclerosis
Via ACCESS Newswire
News headline image
BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform
Via ACCESS Newswire
News headline image
BioNxt Reports Sublingual Cladribine Multiple Sclerosis Drug Milestones Including Large-Animal Study for Validation and Dosing Optimization
Via ACCESS Newswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.